GlassScriptPhysician profile
Hajrunisa Cubro
NPI 1649730136
$1,165.11
in general payments reported to CMS, 2019-2025
17 companies · $527 in 2025
The $527 reported for 2025 was more than what 76% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2023: $192 · 2024: $310 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $351.72 | 2024-2025 | Novasure, Fluent Fluid Management System, Acessa Provu System |
| Abbvie INC. | $188.34 | 2024-2025 | |
| Becton, Dickinson and Company | $141.51 | 2025 | |
| Myriad Women'S Health, INC. | $79.03 | 2023 | Myrisk |
| Shield Therapeutics INC | $61.07 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $55.87 | 2021-2023 | Keytruda, Lynparza |
| Eisai INC. | $42.82 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $35.52 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.76 | 2025 | |
| Glaxosmithkline, LLC. | $33.51 | 2021 | |
| Sumitomo Pharma America, INC. | $30.52 | 2025 | Myfembree |
| Myriad Genetic Laboratories, INC. | $24.37 | 2023 | Myrisk |
| Astellas Pharma US INC | $23.01 | 2024 | Veozah |
| Organon LLC | $20.62 | 2025 | Nexplanon |
| Baxter Healthcare | $17.08 | 2023 | Tisseel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $13.56 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hajrunisa Cubro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.